CLC bio Provides Bioinformatics Solution for Vaccine Target Development to ACE BioSciences
News Dec 20, 2007
ACE BioSciences, an emerging pharmaceutical company focused on developing novel protein-based vaccines and antibodies to address infectious diseases, and CLC bio have announced a collaborative bioinformatics agreement.
Dr. Ingelise Saunders, Chief Executive Officer at ACE BioSciences said, 'At ACE BioSciences we place considerable emphasis on selecting partners based on their scientific know-how - and in that regard we recognize CLC bio as the leading company within bioinformatics, with a global reputation and internationally renowned experts. We see this collaboration as a significant opportunity to augment and expand our bioinformatics platform to increase efficiency, enhance our analyses, and accelerate our research.'
Dr. Jannick D. Bendtsen, project manager and Senior Scientific Officer at CLC bio commented, 'We are looking forward to this collaboration, which is scientifically interesting and challenging. The implementation of our customized software will streamline and fast-track analysis and further increase statistical confidence in the selection of novel candidates for inclusion in the ACE BioSciences’ development portfolio. Implementation of automated target validation protocols will increase efficiency and the rate of data throughput, improve quality assurance and enhance data security.'
Under the terms of the agreement, CLC bio will upgrade and expand ACE BioSciences' existing bioinformatics platform to ensure the company is taking advantage of the most up-to-date, relevant, and innovative software, including protein vaccine target characterization.
In addition, CLC bio will provide greater integration and cross-referencing capabilities, securing for ACE BioSciences the ability to apply extensive statistical analyses to its databases and laboratory information. CLC bio's customized solution will strengthen ACE BioSciences' ability to compare, rank, and prioritize potential vaccine targets.
The solution provided to ACE BioSciences consists of a number of CLC workbenches for DNA, RNA, and protein sequence analysis, supplemented with customized bioinformatics modules that are proprietary for ACE BioSciences.
Using EBX reagents, researchers have converted the C-terminal carboxylic acid of peptides into a carbon-carbon triple bond - an alkyne (in chemical jargon a "decarboxylative alkynylation"). The alkyne moiety is a very valuable functional group that can be used to further modify the peptides.READ MORE